134 results on '"Moynihan, Ray"'
Search Results
2. Global Media Coverage of the Benefits and Harms of Early Detection Tests
Catalog
Books, media, physical & digital resources
3. Reforming disease definitions: a new primary care led, people-centred approach
4. Association of Preferences for Papillary Thyroid Cancer Treatment With Disease Terminology: A Discrete Choice Experiment
5. Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences: A Randomized Crossover Trial
6. Australia is responding to the complex challenge of overdiagnosis.
7. How different terminology for ductal carcinoma in situ (DCIS) impacts women's concern and management preferences: A qualitative study.
8. Wise choices: making physiotherapy care more valuable.
9. Australia is responding to the complex challenge of overdiagnosis
10. Preventing Media-Based False Hopes—Reply
11. Doctors and drug companies: Is the dangerous liaison drawing to an end?
12. Fármacos para la preosteoporosis: ¿prevención o alarmismo ante una enfermedad?.
13. Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals.
14. Drugs for pre-osteoporosis: prevention or disease mongering?
15. Alosetron: a case study in regulatory capture, or a victory for patients' rights?
16. Selling sickness: the pharmaceutical industry and disease mongering.
17. LÍDERES DE OPINIÓN ¿Expertos independientes o representantes farmacéuticos encubiertos?.
18. The Recovery—a podcast about action for sustainable healthcare
19. The marketing of a disease: female sexual dysfunction
20. The making of a disease: female sexual dysfunction
21. Toward a Healthier Patient Voice: More Independence, Less Industry Funding
22. Promises and perils of using genetic tests to predict risk of disease
23. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study
24. Covid-19: an opportunity to reduce unnecessary healthcare
25. Commercial influence and covid-19
26. Can we truly have faith in clinical guidelines? A new Australian study shows cause for 'huge concern' in relation to guideline writers' undisclosed ties to pharma.
27. Improving coverage of medical research in a changing media environment
28. Pathways to independence: towards producing and using trustworthy evidence
29. Commercial interests, transparency, and independence: a call for submissions
30. CHAMP: a novel collaboration between public health and the media.
31. Making medical journalism healthier.
32. Renaming low risk conditions labelled as cancer
33. The Christmas gift of genetic uncertainty
34. Mapping the drivers of overdiagnosis to potential solutions
35. Winding back the harms of too much medicine
36. Drug maker’s PR firm is force behind blood clot awareness campaign
37. Drug marketing: Key opinion leaders: independent experts or drug representatives in disguise?
38. Doctors’ education: the invisible influence of drug company sponsorship
39. Too much medicine?
40. Walking the tightrope: communicating overdiagnosis in modern healthcare
41. “Informed choice” in a time of too much medicine—no panacea for ethical difficulties
42. Authors’ reply to Timms and Bird
43. e-Health records: beware of assumed benefit.
44. Controversy grows over redefinition of gestational diabetes.
45. Domestic violence: can doctors do more to help?
46. Kissing goodbye to key opinion leaders.
47. When less can mean more.
48. Time to debate one-click transparency.
49. A healthy dose of disinvestment.
50. A watchdog to bite the giants?
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.